New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 2, 2004, Pages 549-552

  Koltun, Dmitry O ^a   Marquart, Timothy A ^a   Shenk, Kevin D ^a   Elzein, Elfatih ^a   Li, Yuan ^a   Nguyen, Marie ^a   Kerwar, Suresh ^a   Zeng, Dewan ^a   Chu, Nancy ^a   Soohoo, Daniel ^a   Hao, Jia ^a   Maydanik, Victoria Y ^a   Lustig, David A ^a   Ng, Khing Jow ^a   Fraser, Heather ^a   Zablocki, Jeffery A ^a  

^a Department of Bioorganic Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMIDE; CARDIAC AGENT; CVT 3501; CYTOCHROME P450; PALMITOYL COENZYME A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; FATTY ACID OXIDATION; GUINEA PIG; HEART MITOCHONDRION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; ISOLATED HEART; METABOLISM; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0347360233     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.093     Document Type: Article

References (15)

1. Schofield R.S., Hill J.A. Am. J. Cardiovasc. Drugs. 1:2001;23.
2. McCormack J.G., Stanley W.C., Wolff A.A. Gen. Pharm. 30:1998;639.
3. McCormack J.G., Barr R.L., Wolff A.A., Lopaschuk G.D. Circulation. 93:1996;135.
4. Nedergaard J., Cannon B. Methods Enzymol. 55:1979;3.
5. Shiratsuchi M., Kawamura K., Akashi T., Ishihama H., Nakamura M., Takenaka F. Chem. Pharm. Bull. 35:1987;3691.
6. 2NH).
7. Oshiro Y., Sakurai Y., Tanaka T., Kikuchi T., Hirose T., Tottori K. J. Med. Chem. 34:1991;2014.
8. 1H NMR.
9. 1H NMR. All resin-bound reagents were obtained from Argonaut Technologies.
10. Lazzara R.; Scherlag G. J.; Belardinelli L. 2002. Atrioventricular Conduction. In Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Approaches; Spooner, P. M, Rosen, M. R., Eds.; Marcel Dekker; New York, Basel; p 265.
11. Compounds were formulated as x·HCl salts by treatment with excess HCl to assist solubility and administered with 5% DMSO and 0.9 M NaCl.
12. Tassaneeyakul W., Birkett D., Veronese M., McManus M., Tukey R., Quattrochi L., Gelboin H., Miners J. J. Pharmacol. Exp. Ther. 265:1993;401.
13. Scmitz G., Lepper H., Estler C. J. Chromatogr. 620:1993;158.
14. Leemann T., Transom C., Dayer P. Life Sci. 52:1993;29.
15. Wienkers L., Steenwyck R., Pearson P. Drug Metab. Dispos. 23:1995;383.